IL-6和动脉粥样硬化性缺血性卒中的关系研究进展

doi:10.3969/j.issn.1673-5765.2022.09.018

摘要/Abstract

摘要： 缺血性卒中是一种病因复杂的综合征，其中动脉粥样硬化是主要病因之一。流行病学、分子生物学证据表明IL-6促进动脉粥样硬化斑块的形成和生长，影响缺血性卒中的发生、发展及预后。新近的临床研究进一步证实干预IL-6通路有望成为缺血性卒中治疗的新靶点。本综述从分子生物学、流行病学和新近开展的临床研究阐述IL-6在缺血性卒中发生、预后中的作用，以及作为潜在治疗靶点的可能性。

文章导读： 结合近来报道的干预IL-6通路具有预防心血管疾病复发的作用，本综述通过总结IL-6在缺血性卒中发生、发展和预后中的作用，为缺血性卒中治疗新靶点的筛选提供证据。

关键词: 缺血性卒中; 动脉粥样硬化; 白介素-6; 炎症; 心血管疾病

Abstract: Ischemic stroke is a complex syndrome, and atherosclerosis is one of the main causes. Interleukin 6 (IL-6) is an important inflammatory factor involved in atherosclerosis. The epidemiological and molecular biological evidence indicated that IL-6 can promote the formation and growth of atherosclerosis plaque and influence the occurrence, development and prognosis of ischemic stroke. Recent clinical studies further suggested IL-6 may be a potential therapeutic target of ischemic stroke. This review aimed to elaborate the role of IL-6 in the occurrence and prognosis of ischemic stroke from the perspectives of molecular mechanism, epidemiology and clinical research.

Key words: Ischemic stroke; Atherosclerosis; Interleukin 6; Inflammation; Cardiovascular disease

龚宇田, 黎洁洁. IL-6和动脉粥样硬化性缺血性卒中的关系研究进展[J]. 中国卒中杂志, 2022, 17(09): 1022-1026.

GONG Yutian, LI Jiejie. Advances in the Relationship between IL-6 and Atherosclerotic Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(09): 1022-1026.

参考文献

[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志，2020，35（9）：833-854.
[2] 史怀璋，李斗，李慎茂，等. 经DSA分析1000例缺血性脑血管病华人患者的病因特点[J]. 中国脑血管病杂志，2005，2（10）：437-440.
[3] WOLF J，WAETZIG G H，REINHEIMER T M，et al. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing[J]. Biochem Biophys Res Commun，2016，470（4）：870-876.
[4] 张伟洁，郑宏. IL-6介导免疫炎性反应作用及其与疾病关系的研究进展[J]. 细胞与分子免疫学杂志，2017，33（5）：699-703.
[5] MIYAURA C，ONOZAKI K，AKIYAMA Y，et al. Recombinant human interleukin 6（B-cell stimulatory factor 2）is a potent inducer of differentiation of mouse myeloid leukemia cells（M1）[J]. Febs Letters，1988，234（1）：17-21.
[6] MINAMI M，INOUE M，WEI S，et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line[J]. Proc Natl Acad Sci USA，1996，93（9）：3963-3966.
[7] LEE P C，HO I C，LEE T C. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1，monocyte chemoattractant protein-1，and interleukin-6 in vascular smooth muscle cells[J]. Toxicol Sci，2005，85（1）：541-550.
[8] SCHUETT H，LUCHTEFELD M，GROTHUSEN C，et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis[J]. Thromb Haemost，2009，102（2）：215-222.
[9] HÄGG D，SJÖBERG S，HULTÉN L M，et al. Augmented levels of CD44 in macrophages from atherosclerotic subjects：a possible IL-6-CD44 feedback loop?[J]. Atherosclerosis，2007，190（2）：291-297.
[10] CHEHBOUN S，LABRECQUE-CARBONNEAU J，PASQUIN S，et al. Epstein-Barr virus-induced gene 3（EBI3）can mediate IL-6 trans-signaling[J]. J Biol Chem，2017，292（16）：6644-6656.
[11] HANSSON G K，HERMANSSON A. The immune system in atherosclerosis[J]. Nat Immunol，2011，12（3）：204-212.
[12] GREDAL H，THOMSEN B B，BOZA-SERRANO A，et al. Interleukin-6 is increased in plasma and cerebrospinal fluid of community-dwelling domestic dogs with acute ischaemic stroke[J]. Neuroreport，2017，28（3）：134-140.
[13] SONG J W，SONG K S，CHOI J R，et al. Plasma level of IL-6 and its relationship to procoagulant and fibrinolytic markers in acute ischemic stroke[J]. Yonsei Med J，2006，47（2）：201-206.
[14] ACALOVSCHI D，WIEST T，HARTMANN M，et al. Multiple levels of regulation of the interleukin-6 system in stroke[J]. Stroke，2003，34（8）：1864-1869.
[15] WAJE-ANDREASSEN U，KRÅKENES J，ULVESTAD E，et al. IL-6：an early marker for outcome in acute ischemic stroke[J]. Acta Neurol Scand，2005，111（6）：360-365.
[16] SMITH C J，EMSLEY H C，GAVIN C M，et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume，stroke severity and long-term outcome[J/OL]. BMC Neurol，2004，4：2[2022-03-02]. https://doi.org/10. 1186/1471-2377-4-2.
[17] 吴章薇，张通，赵军，等. 急性缺血性卒中后炎症因子水平与神经功能恢复的关系研究[J]. 中国卒中杂志，2021，16（10）：1023-1028.
[18] RIDKER P M，RIFAI N，STAMPFER M J，et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men[J]. Circulation，2000，101（15）：1767-1772.
[19] DANESH J，KAPTOGE S，MANN A G，et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease：two new prospective studies and a systematic review[J/OL]. PLoS Med，2008，5（4）：e78[2022-03-02]. https://doi.org/10. 1371/journal.pmed.0050078.
[20] CHEN M，YANG Y. A meta-analysis on associations of IL-6 and IL-10 polymorphisms with susceptibility to ischemic stroke[J/OL]. J Neuroimmunol，2019，335：577004[2022-03-02]. https://doi.org/10.1016/j.jneuroim.2019.577004.
[21] CAINZOS-ACHIRICA M，ENJUANES C，GREENLAND P，et al. The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death：the multi-ethnic study of atherosclerosis（MESA）[J/OL]. Atherosclerosis，2018，278：217-225[2022-03-02]. https://doi.org/10.1016/j.atherosclerosis.2018.09.034.
[22] JENNY N S，CALLAS P W，JUDD S E，et al. Inflammatory cytokines and ischemic stroke risk：the REGARDS cohort[J/OL]. Neurology，2019，92（20）：e2375-e2384[2022-03-02]. https://doi. org/10. 1212/WNL. 0000000000007416.
[23] IL6R Genetics Consortium Emerging Risk Factors Collaboration，SARWAR N，BUTTERWORTH A S，et al. Interleukin-6 receptor pathways in coronary heart disease：a collaborative meta-analysis of 82 studies[J]. Lancet，2012，379（9822）：1205-1213.
[24] KAPTOGE S，SESHASAI S R，GAO P，et al. Inflammatory cytokines and risk of coronary heart disease：new prospective study and updated meta-analysis[J]. Eur Heart J，2014，35（9）：578-589.
[25] RIDKER P M，EVERETT B M，THUREN T，et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med，2017，377（12）：1119-1131.
[26] RIDKER P M. Testing the inflammatory hypothesis of atherothrombosis：scientific rationale for the cardiovascular inflammation reduction trial（CIRT）[J/OL]. J Thromb Haemost，2009，7 Suppl 1：332-339[2022-03-02]. https://doi.org/10.1111/j.1538-7836.2009.03404.x.
[27] NIDORF S M，EIKELBOOM J W，BUDGEON C A，et al. Low-dose colchicine for secondary prevention of cardiovascular disease[J]. J Am Coll Cardiol，2013，61（4）：404-410.
[28] TARDIF J C，KOUZ S，WATERS D D，et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med，2019，381（26）：2497-2505.
[29] KELLY P，WEIMAR C，LEMMENS R，et al. Colchicine for prevention of vascular inflammation in non-cardioembolic stroke（CONVINCE）-study protocol for a randomised controlled trial[J]. Eur Stroke J，2021，6（2）：222-228.